Discounted Cash Flow
Esperion Therapeutics, Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | — | $-75.0m | $-47.8m | — | $-3.33 |
| 2017 | — | $-167.0m (-122.7%) | $-131.3m (-174.6%) | — | $-6.98 (-109.6%) |
| 2018 | $0 | $-201.8m (-20.9%) | $-148.8m (-13.3%) | — | $-7.54 (-8.0%) |
| 2019 | $148.4m | $-97.2m (51.9%) | $-71.3m (52.1%) | -65.5% | $-3.59 (52.4%) |
| 2020 | $227.5m (53.4%) | $-143.6m (-47.7%) | $-86.0m (-20.7%) | -63.1% (3.7%) | $-5.23 (-45.7%) |
| 2021 | $78.4m (-65.5%) | $-269.1m (-87.5%) | $-263.8m (-206.6%) | -343.0% (-443.8%) | $-9.31 (-78.0%) |
| 2022 | $75.5m (-3.8%) | $-233.7m (13.2%) | $-174.8m (33.7%) | -309.6% (9.8%) | $-3.52 (62.2%) |
| 2023 | $116.3m (54.1%) | $-209.2m (10.4%) | $-135.5m (22.5%) | -179.9% (41.9%) | $-2.03 (42.3%) |
| 2024 | $332.3m (185.7%) | $-51.7m (75.3%) | $-24.0m (82.3%) | -15.6% (91.3%) | $-0.28 (86.2%) |
| 2025 | $403.1m (21.3%) | $-22.7m (56.2%) | $-13.1m (45.4%) | -5.6% (63.9%) | $-0.11 (60.7%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.